Grants Search Results

This grant funds a student to complete work in pediatric oncology research for the summer. The team will identify factors for metastasis at primary childhood cancer diagnosis, as metastases account for 2/3 of cancer-related deaths. By uncovering these factors, they seek to promote early detection and ultimately reduce cancer mortality. Additionally, they aim to investigate factors influencing survival in pediatric patients with metastatic cancer, with a particular focus on socioeconomic determinants such as neighborhood income and education levels. The findings will help identify high-risk populations and inform strategies to prevent poor outcomes. Their approach will integrate traditional epidemiology methods with artificial intelligence techniques to develop an optimal predictive model. In the future, this model can be used to estimate an individual's metastasis risk before it occurs using patient information inputs. Overall, this study aims to advocate for more sophisticated methods to generate clinically meaningful insights and reduce pediatric cancer deaths in society. This work is being completed under the mentorship of Dr. Kim Johnson.

Acute myeloid leukemia (AML) is a blood cancer that affects children. AML treatment involves intensive chemotherapy that requires over 140 days in the hospital. This places immense financial burden on families including medical bills, transportation costs, childcare, and missed days from work. This burden and resulting distress are called financial toxicity. Dr. Zheng's research is focused on measuring financial toxicity and trying to figure out what can be done about it. One important idea to consider is that many parents quit their jobs or reduce their hours to care for their child. Dr. Zheng plans to use surveys and interviews to gain a clearer picture of how work disruptions develop over AML treatment and lead to financial toxicity. Dr. Zheng wants to identify what work arrangements and policies could offer the most support. Ultimately, it could lead to advocating for more flexible work schedules, remote work options, or other accommodations that could make a real difference for these families.

Survivors of pediatric brain tumors have a high risk of medical problems that can negatively affect the quality of their lives. Particularly concerning are effects on brain development, including learning and emotional well-being, and metabolism, which can lead to obesity and muscle loss. There is an urgent need for tools that can better predict which children are most at risk so that they can be offered treatments to prevent these problems. Dr. Kann's and colleagues have developed medical imaging tools that use artificial intelligence on routine brain scans to track and predict 1) muscle weakness and malnutrition, and 2) brain development in children. Dr. Kahn and team will test these tools in large datasets from hospitals and clinical trials of pediatric brain tumor patients and survivors to predict the risk of these negative effects in each patient. The tools developed may be used in clinical trials to improve quality-of-life for childhood brain tumor survivors.

Even after being cured, childhood cancer survivors face challenges to living a healthy life, and one major challenge is heart disease. Heart health is closely linked to healthy eating, but many survivors cannot eat as healthily as they want because they don't have access to, or can't afford, healthy foods ("food insecurity"). Dr. Aziz-Bose will enroll survivors in this study to ask what they are eating, and understand whether they experience food insecurity and other conditions that put heart health at risk. Survivors will also be interviewed for their ideas about how to support healthy eating, including the best ways to directly give families healthy foods, an approach called "food is medicine." Using this information, Dr. Aziz-Bose will fine-tune a "food is medicine" intervention that she developed, and test it on a larger scale to see its impact on food insecurity and heart health. The goal being to understand and tackle barriers to healthy eating so all survivors can have the best health possible.

This grant is funded by Allied World, a global provider of insurance and reinsurance solutions.

Modern therapies such as stem cell transplant and immune therapy have made high-risk neuroblastoma a survivable disease for some children, but little is known about the chronic health issues experienced by survivors. In order to ensure that future treatments address both the chance and the quality of cure, this consortium aims to examine the impact of neuroblastoma therapy on survivors' growth, pubertal development and long-term health.

This grant is named for and funded by the "Just Do It...…and be done with it" Hero Fund created in honor of Sara Martorano who doesn't let anything dim her sparkle and has a compassionate heart and smile. It also celebrates the courage of all cancer kids through treatment and the support of their family and friends.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: LEAHRN (Late Effects After High Risk Neuroblastoma) Consortium. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL.

While great strides have been made in treating children with acute leukemia, some children continue to do poorly. For example, children of Hispanic ethnicity are at greater risk of both relapse and treatment-related complications. The Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium will expand and enhance the recently established network of childhood cancer centers, with the goal of tackling ethnic outcome disparities by generating an unmatched resource of clinical information and biological samples. This information will be used to predict those who have the greatest risk of poor outcomes, with a focus on Hispanics, to improve prevention and treatment strategies. Funds administered by Baylor College of Medicine.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

Anthracycline chemotherapies are important, lifesaving medicines given to a majority of children with cancer. However, they can injure the heart and cause heart failure in up to 10% of children years later, during cancer survivorship. Unfortunately, with the current available tools, there is not much known about which children will develop heart failure and what treatments would work best for them, and by the time the problem is identified it may be too late to help them. Dr. Narayan seeks to address this problem by using state-of-the-art, in-depth imaging techniques in adolescent and young adult survivors of childhood cancer to detect early changes in the heart. The goal is to develop new tools to provide early, personalized treatments to prevent heart failure.

This grant is named for TEAM ABBY Gives, a St. Baldrick's Hero Fund. Abby was diagnosed with Pre-B ALL when she was almost five years old. She had a successful bone marrow transplant, but battle battled graft vs. host disease (GVHD) and heart disease for years. Abby and her treatment team worked hard over many years to keep the GVHD in check. Sadly, Abby passed away on October 19, 2021. This fund unites the incredible support of family and friends in Abby's memory and inspires others to join the fight for cures and better treatments.

Though most children with cancer are able to be cured, some children are more likely to be cured than others, even with the best available treatments. Childhood cancer treatment is a long and difficult process for children and their families, and most families need support from those around them including community support and resources. Adults with cancer living in disadvantaged communities are much more likely to die from their cancer, though much less is known about how the characteristics of the community impact outcomes for children with cancer. Dr. Hoppmann uses a large national cancer database, coupled with measures of social determinants of health (measures of poverty, healthcare access, educational attainment, social and physical environment) to determine how these community vulnerabilities impact children with cancer. Results will help ensure gains made in pediatric cancer are shared equitably among all children, including those from disadvantaged areas.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.